MedTrace Logo

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

NCT01154829 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2016-05-26

No results posted yet for this study

Summary

The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, the investigators want to examine the influence of D2 receptor blockade on these disturbances. The investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect D2 receptor blockade to reverse some of the functional and cognitive impairments.

Conditions

Interventions

DRUG

amisulpride

Individually dosed, according to symptoms, for a period of 6 weeks

DRUG

aripiprazole

Individually dosed, according to symptoms, for a period of 6 weeks

Sponsors & Collaborators

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Institute of Psychiatry, London

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Copenhagen Hospital Corporation

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Birte Y Glenthoj, professor · University of Copenhagen, Psychiatric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2014-05-31
Completion
2016-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154829 on ClinicalTrials.gov